secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001193125-24-243431
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines reports RMC-9805 clinical data: 30% ORR in 2L+ PDAC at 1,200 mg/day
--------------------------------------------------------------------------------

- RMC-9805 monotherapy showed no Grade 4/5 TRAEs, no discontinuations; 3% dose reduction rate overall (179 patients).
- For 2L+ PDAC patients (n=40) at 1,200 mg/day, ORR 30% (confirmed + pending), DCR 80%.
- Most common any-grade TRAEs at 1,200 mg/day: nausea (27%), diarrhea (20%), vomiting (15%), rash (10%).
- Median treatment duration 2.8 months across all doses; data cutoff September 2, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312524243431/0001193125-24-243431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312524243431/d890891d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-243431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer